Tirzepatide
Tirzepatide is developed for type 2 diabetes and chronic weight management. It improves glycemic control, suppresses appetite, delays gastric emptying, and promotes fat metabolism through dual-receptor action, delivering stronger weight loss (up to 15–22% of body weight) than single GLP‑1 agonists.
| 5mg*10vials | $30 | 40mg*10vials | $150 |
| 10mg*10vials | $50 | 50mg*10vials | $165 |
| 15mg*10vials | $70 | 60mg*10vials | $200 |
| 20mg*10vials | $90 | 100mg*10vials | $285 |
| 30mg*10vials | $110 | 120mg*10vials | $310 |
Product Information
What is Tirzepatide?
Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight management) is a once-weekly injectable prescription medication. It is a dual GLP‑1/GIP receptor agonist that acts on natural gut hormones to reduce appetite, increase fullness, stabilize blood sugar, and support significant weight loss.
Approved Uses
- For adults with type 2 diabetes to improve blood sugar control alongside diet and exercise.
- For adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related conditions (such as high blood pressure, high cholesterol, or sleep apnea) for long-term weight management.
How It Works
- Lowers hunger and reduces food cravings.
- Increases feelings of fullness, leading to lower calorie intake.
- Slows stomach emptying.
- Improves blood sugar regulation and insulin sensitivity.
- Supports consistent, sustained fat loss when combined with lifestyle changes.
How to Use
- Administered as a subcutaneous injection (abdomen, thigh, or upper arm).
- Dosed once per week, on the same day each week (flexible timing).
- Starting dose: 2.5 mg once weekly for 4 weeks (to improve tolerance).
- Dosage may be increased by 2.5 mg every 4 weeks.
- Maximum recommended dose: 15 mg once weekly.
Expected Effects
- Significant weight loss: many users lose 15–25 kg (33–55 lbs) over 68 weeks with diet and exercise.
- At higher doses, a large percentage of people lose 20% or more of body weight.
- Improved blood sugar, blood pressure, and lipid profiles.
Important Warnings & Contraindications
Do NOT use if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC).
- Have multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Are pregnant, planning pregnancy, or breastfeeding.
- Have a history of severe pancreatitis.
- Are allergic to tirzepatide or any inactive ingredients.
Associated Products
Related Experimental Studies
